Russian researchers say vaccine 'promising'

Russian researchers say vaccine 'promising'

The three drug companies developing vaccines for COVID-19 are considering issuing a joint public statement that they will not seek emergency governmental approval until there is "substantial evidence of safety and efficacy" of their inoculations, The Wall Street Journal is reporting.

Neal Browning receives a shot in the first-stage safety study clinical trial of a potential vaccine for Covid-19 at the Kaiser Permanente Washington Health Research Institute in Seattle on March 16, 2020.

The Russian government officially approved Sputnik V in August without waiting for the results of the final phase 3 clinical tests.

The World Health Organization (WHO) has moved to secure an initial 230 million doses of Covid-19 vaccines for Africa, while also advocating that any vaccine in development should also be tested on the continent. The authors also object to a plan that would prioritise countries according to the number of frontline health care workers, the proportion of the population over 65, and the number of people with comorbidities within each country.

Ehanire stated that Nigeria has been participating in series of knowledge-exchange and contacts with different research bodies and countries to find solutions to the COVID-19 challenge and has contacted the Embassy of the Russian Federation in Nigeria for right of access immediately the Russian COVID-19 Vaccine was announced.

The Russian vaccine is behind other candidates, including the jab developed by researchers at Oxford University, who are already conducting global phase three trials.

On Friday, independent experts said results were weakened by the fact the trial was both open-label and non-randomised, meaning participants knew they were getting a vaccine, raising the chance of a placebo effect, and were not chosen at random, meaning doctors may have tried the drug on only the most healthy.

The editor-in-chief of The Lancet said the results of the studies did not mean that a general vaccine was ready for widespread public use.

The pharmaceutical business Moderna, which is checking a vaccine for Covid -19, stated Friday that it is motivating its trial websites to work harder to hire varied populations, even if those efforts slow the speed of registration.

This week the USA urged states to get ready for a potential COVID-19 vaccine rollout two days before the presidential election in November, sparking concerns President Donald Trump's administration is accelerating research to fit a political timetable.

"We'd like to see a vaccine with at least 50 percent efficacy, preferably higher", she said.

"The vaccine's immune response documented now among volunteers is enough to counter any dose of Covid-19 that you could imagine", Gintsburg said.

Related Articles